Kelly Gold Purchases 10,000 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CFO Kelly Gold bought 10,000 shares of the stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the acquisition, the chief financial officer directly owned 10,000 shares of the company’s stock, valued at approximately $39,600. The trade was a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Kelly Gold also recently made the following trade(s):

• On Monday, August 3rd, Kelly Gold purchased 6,551 shares of CAMP4 Therapeutics stock. The stock was bought at an average price of $1.65 per share, for a total transaction of $10,809.15.

CAMP4 Therapeutics Price Performance

CAMP stock traded up $0.01 on Wednesday, reaching $3.80. 132,086 shares of the company traded hands, compared to its average volume of 268,681. The firm has a fifty day simple moving average of $4.11 and a 200-day simple moving average of $4.34. The company has a market cap of $238.45 million, a P/E ratio of -1.64 and a beta of 0.27. CAMP4 Therapeutics Corporation has a one year low of $1.41 and a one year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. On average, sell-side analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CAMP. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. UBS Group set a $15.00 price target on CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $9.56.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Jupiter Topco LLC purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth $27,581,000. Janus Henderson Group PLC raised its stake in shares of CAMP4 Therapeutics by 35.9% in the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after buying an additional 1,666,666 shares during the period. 5AM Venture Management LLC purchased a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at about $25,647,928. Vivo Capital LLC lifted its position in shares of CAMP4 Therapeutics by 8.3% during the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after buying an additional 325,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of CAMP4 Therapeutics during the 4th quarter valued at approximately $14,938,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.